Inotad 100mg/5ml Injection (Irinotecan Injection IP)

Inotad 100mg Injection is a prescription cytotoxic medicine containing irinotecan at 20mg/ml. Irinotecan Injection is a topoisomerase I inhibitor used mainly in gastrointestinal oncology, especially colorectal cancer, either in combination regimens or as later-line therapy. The 100mg/5ml vial is a concentration/presentation, not a patient dose. Irinotecan Injection IP dosing is protocol-specific and calculated using body surface area (mg/m²).

Dose selection depends on regimen, previous treatment, bilirubin/liver function, blood counts, toxicity and sometimes UGT1A1 genotype/phenotype considerations. However, Irinotecan 100mg Injection has two characteristic high-risk toxicities: diarrhea and myelosuppression. Early diarrhea can occur with an acute cholinergic syndrome during or shortly after infusion; late diarrhea can be prolonged, severe and life-threatening.

Inotad Injection should be used only for an appropriate specialist-directed indication. The exact treatment setting, combination regimen and duration depend on the diagnosis and current clinical guidance.
Metastatic colorectal cancer - combination therapy: Irinotecan 100mg is used with fluorouracil/leucovorin-based regimens as part of first-line or subsequent treatment strategies depending on the clinical setting.
Metastatic colorectal cancer after progression: Inotad 100mg Injection is indicated as single-agent treatment for patients whose disease has recurred or progressed after fluorouracil-based therapy under established labeling.
Other protocol uses: Irinotecan Injection is incorporated into specialist regimens in other cancers in some guidelines. Such uses should be described only when tied to the relevant disease protocol rather than generalized from the colorectal indication.

Irinotecan 100 mg is converted into its active metabolite known as SN-38. This compound inhibits an enzyme known as topoisomerase I. Topoisomerase I normally assists in unwinding and repairing the DNA chain. When this process is inhibited, DNA is left damaged; thus, multiplication of cancerous cells becomes impossible and ultimately they die.

• Irinotecan 100mg Injection has proven to be an efficient drug regimen in treating metastatic colorectal cancer through clinical trials. It can be used in combination with fluoropyrimidines or in the event that the cancer develops resistance after administration of fluorouracil therapy.
  
• Outcome of treatment varies depending on the type of regimen, nature of the cancer, treatment stage, and other medicines used.
  
• Contemporary treatment of colorectal cancer can also involve the use of targeted medicines or immunotherapy in patients with certain molecular characteristics.
  
• All the information provided pertains to irinotecan Injection and certain regimens, not to a specific clinical trial of the medicine vial.
  

Common or clinically relevant adverse effects can include:

• Early or late diarrhea
  
• Nausea
  
• Vomiting
  
• Neutropenia
  
• Anemia
  
• Fatigue
  
• Alopecia
  
• Abdominal cramping
  
• Loss of appetite

Serious adverse reactions can include:

• Life-threatening late diarrhea and dehydration
  
• Severe neutropenia/febrile neutropenia/sepsis
  
• Acute cholinergic syndrome
  
• Interstitial pulmonary disease
  
• Severe hypersensitivity
  
• Renal failure secondary to volume depletion
  
• Increased toxicity in patients with reduced UGT1A1 activity

Patients should receive medicine-specific instructions about symptoms that require urgent medical attention.

Inotad 100mg Injection is not self-administered. The 100mg/5ml (20mg/ml) presentation is used to prepare a protocol-calculated dose in a healthcare setting.

These are molecule-level examples/principles from regulatory labeling and are not instructions for self-dosing. The healthcare specialist determines the actual dose, duration, dose modifications and supportive treatment.

Irinotecan Injection is administered on scheduled chemotherapy days. If an infusion is delayed or missed, the oncology team determines the revised cycle based on blood counts, diarrhea recovery, organ function and the treatment protocol. Patients should never attempt to compensate for a missed infusion.

Monitoring is individualized according to the disease, regimen and patient risk factors. It may include:

• CBC with differential
  
• Diarrhea frequency/severity and hydration
  
• Electrolytes and renal function during significant diarrhea
  
• Liver tests and bilirubin
  
• Fever/infection
  
• Pulmonary symptoms
  
• UGT1A1 status when clinically appropriate
  
• Tumour response
  

1. DailyMed. CAMPTOSAR (irinotecan hydrochloride) prescribing information, updated May 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e518dfc6-7e93-4fee-a66c-51e1ab71c056​
2. Current colorectal-cancer treatment guidelines and protocol-specific irinotecan regimens https://esmed.org/irnotecan-dose-adjustment-in-colorectal-cancer-treatment/​
3. Current India-specific Inotad package insert before publication https://www.researchgate.net/publication/50434421_Package_Inserts_in_India_Need_for_a_Revision​
4. Brand-specific Inotad prescribing information/package insert should remain the primary source for manufacturer, exact presentation, storage, pack configuration and India-specific approved labeling before publication https://www.researchgate.net/publication/312630060_Analysis_of_package_inserts_of_orally_administered_drugs_available_in_the_Indian_market​
5. National Cancer Institute. Colon Cancer Treatment (PDQ®)–Health Professional Version. NCI https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq​